GRK2 up-regulation creates a positive feedback loop for catecholamine production in chromaffin cells

Molecular Endocrinology

Volumn 30, Issue 3, 2016, Pages 372-381

  Jafferjee, Malika ^a   Valero, Thairy Reyes ^a   Marrero, Christine ^a   McCrink, Katie A ^a   Brill, Ava ^a   Lymperopoulos, Anastasios ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEUROHORMONE; PROTEIN TYROSINE KINASE; TYROSINE 3 MONOOXYGENASE; G PROTEIN COUPLED RECEPTOR KINASE 5; GPRK5 PROTEIN, RAT; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NORADRENALIN;

ADRENAL MEDULLA; ADRENERGIC SYSTEM; ANIMAL CELL; APOPTOSIS; ARTICLE; CATECHOLAMINE SYNTHESIS; CELL SURVIVAL; CHROMAFFIN CELL; CONTROLLED STUDY; HEART FAILURE; HOMEOSTASIS; MALE; NONHUMAN; PC12 CELL LINE; POSITIVE FEEDBACK; PRIORITY JOURNAL; RAT; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; DRUG EFFECTS; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGICAL FEEDBACK; SPRAGUE DAWLEY RAT;

ANIMALS; CATECHOLAMINES; CELL SURVIVAL; CHROMAFFIN CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEEDBACK, PHYSIOLOGICAL; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 5; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; HUMANS; MALE; MODELS, BIOLOGICAL; NOREPINEPHRINE; PC12 CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-2; SRC-FAMILY KINASES; SYMPATHETIC NERVOUS SYSTEM; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84959492573     PISSN: 08888809     EISSN: 19449917     Source Type: Journal    
DOI: 10.1210/me.2015-1305     Document Type: Article

References (32)

1. Mudd JO, Kass DA. Tackling heart failure in the twenty first century. Nature. 2008;451:919–928.
2. Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113: 739–753.
3. Lymperopoulos A, Rengo G, Funakoshi H, Eckhart AD, Koch WJ. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat Med. 2007;13:315–323.
4. Lymperopoulos A, Rengo G, Gao E, Ebert SN, DornGW2nd, Koch WJ. Reduction of sympathetic activity via adrenal-targeted GRK2 gene deletion attenuates heart failure progression and improves cardiac function after myocardial infarction. J Biol Chem. 2010; 285:16378–16386.
5. Rengo G, Lymperopoulos A, Zincarelli C, et al. Blockade of β-adrenoceptors restores the GRK2-mediated adrenal α(2)-adrenoceptor-catecholamine production axis in heart failure. Br J Pharmacol. 2012;166:2430–2440.
6. Nguyen K, Kassimatis T, Lymperopoulos A. Impaired desensitization of a human polymorphic α 2B-adrenergic receptor variant enhances its sympatho-inhibitory activity in chromaffin cells. Cell Commun Signal. 2011;9:5.
7. 2-adrenergic receptor signaling towards increased contractility. Cell Commun Signal. 2013;11:64.
8. Uhlén S, Dambrova M, Näsman J, et al. [3H]RS79948–197 binding to human, rat, guinea pig and pig α 2A, α 2B-and α 2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur J Pharmacol. 1998;343:93–101.
9. Bathgate-Siryk A, Dabul S, Pandya K, et al. Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension. 2014;63:404–412.
10. Williams NG, Zhong H, Minneman KP. Differential coupling of α 1-, α 2-, and β-adrenergic receptors to mitogen-activated protein kinase pathways and differentiation in transfected PC12 cells. J Biol Chem. 1998;273:24624–24632.
11. Penn RB, Pronin AN, Benovic JL. Regulation of G protein-coupled receptor kinases. Trends Cardiovasc Med. 2000;10:81–89.
12. Lymperopoulos A, Rengo G, Koch WJ. Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. Trends Mol Med. 2007;13:503–511.
13. Hein L. Adrenoceptors and signal transduction in neurons. Cell Tissue Res. 2006;326:541–551.
14. Cassé C, Giannoni F, Nguyen VT, Dubois MF, Bensaude O. The transcriptional inhibitors, actinomycin D and α-amanitin, activate the HIV-1 promoter and favorphosphorylation of the RNA polymerase II C-terminal domain. J Biol Chem. 1999;274:16097–16106.
15. Luttrell DK, Luttrell LM. Not so strange bedfellows: G-proteincoupled receptors and Src family kinases. Oncogene. 2004;23: 7969–7978.
16. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the α 2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;390:88–91.
17. Zheng H, Loh HH, Law PY. β-Arrestin-dependent μ-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol Pharmacol. 2008;73:178–190.
18. Csató V, Peto˝ A, Koller A, Édes I, Tóth A, Papp Z. Hydrogen peroxide elicits constriction of skeletal muscle arterioles by activating the arachidonic acid pathway. PLoS One. 2014;9:e103858.
19. Vartiainen N, Keksa-Goldsteine V, Goldsteins G, Koistinaho J. Aspirin provides cyclin-dependent kinase 5-dependent protection against subsequent hypoxia/reoxygenation damage in culture. J Neurochem. 2002;82:329–335.
20. Hein L, Altman JD, Kobilka BK. Two functionally distinct α 2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 1999;402:181–184.
21. Llorente J, Lowe JD, Sanderson HS, et al. μ-Opioid receptor desensitization: homologous or heterologous? Eur J Neurosci. 2012;36: 3636–3642.
22. Kaye D, Esler M. Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res. 2005;66:256–264.
23. Aggarwal A, Esler MD, Lambert GW, Hastings J, Johnston L, Kaye DM. Norepinephrine turnover is increased in suprabulbar subcortical brain regions and is related to whole-body sympathetic activity in human heart failure. Circulation. 2002;105:1031–1033.
24. Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003; 5:659–667.
25. Floras JN. The “unsympathetic” nervous system of heart failure. Circulation. 2002;105:1753–1755.
26. Soltysinska E, Olesen SP, Osadchii OE. Myocardial structural, contractile and electrophysiological changes in the guinea-pig heart failure model induced by chronic sympathetic activation. Exp Physiol. 2011;96:647–663.
27. Tomaszek A, Kiczak L, Bania J, et al. Increased gene expression of catecholamine-synthesizing enzymes in adrenal glands contributes to high circulating catecholamines in pigs with tachycardia-induced cardiomyopathy. J Physiol Pharmacol. 2015;66:227–231.
28. Schneider J, Lother A, Hein L, Gilsbach R. Chronic cardiac pressure overload induces adrenal medulla hypertrophy and increased catecholamine synthesis. Basic Res Cardiol. 2011;106:591–602.
29. Lymperopoulos A, Rengo G, Koch WJ. GRK2 inhibition in heart failure: something old, something new. Curr Pharm Des. 2012;18: 186–191.
30. Pitcher JA, Tesmer JJ, Freeman JL, Capel WD, Stone WC, Lefkowitz RJ. Feedback inhibition of G protein-coupled receptor kinase 2 (GRK2) activity by extracellular signal-regulated kinases. J Biol Chem. 1999;274:34531–34534.
31. 2 channels and adrenal catecholamine release by G protein coupled receptors. Cell Mol Neurobiol. 2010; 30:1201–1208.
32. Lymperopoulos A, Karkoulias G, Koch WJ, Flordellis CS. α2-Adrenergic receptor subtype-specific activation of NF-κB in PC12 cells. Neurosci Lett. 2006;402:210–215.